Recommendations for the use of Hepatitis C virus protease inhibitors for the treatment of chronic Hepatitis C in HIV-infected persons. A position paper of the Italian Association for the Study of Infectious and Tropical Diseases

Orlando Armignacco, Massimo Andreoni, Evangelista Sagnelli, Massimo Puoti, Raffaele Bruno, Giovanni Battista Gaeta, Carlo F. Perno, Teresa A. Santantonio, Paolo Bonfanti, Stefano Bonora, Marco Borderi, Antonella Castagna, Antonella D'Arminio Monforte, Andrea De Luca, Paolo Grossi, Giovanni Guaraldi, Franco Maggiolo, Cristina Mussini, Caterina Sagnelli, Marcello TavioCarlo Torti, Caterina Uberti-Foppa, Gioacchino Angarano, Andrea Antinori, Giampiero Carosi, Antonio Chirianni, Giovanni Di Perri, Massimo Galli, Adriano Lazzarin, Giuliano Rizzardini, Gloria Taliani

Research output: Contribution to journalArticle

Abstract

The efficacy data obtained with boceprevir and telaprevir for persons with hepatitis C virus (HCV) genotype 1 infection raise the question of whether HCV protease inhibitors should be used in human immunodeficiency virus (HIV)/HCV co-infected persons. The Italian Association for the Study of Infectious and Tropical Diseases has made these recommendations to provide the rationale and practical indications for the use of triple anti-HCV therapy in persons living with HIV (PLWHIV). A Writing Committee of experts indicated by the President of the Association and a Consulting Committee contributed to the document. The final draft was submitted to the evaluation of external experts and the text modified according to their suggestions and comments. Treatment of HCV co-infection should be considered for all HCV RNA positive PLWHIV. Response-guided therapy with pegylated interferon and ribavirin is the standard treatment of PLWHIV with infection by HCV genotype 2, 3, 4, 5 and 6. Boceprevir and telaprevir should be used to treat HCV genotype 1 infection in HIV/HCV co-infected patients for 48 weeks on an individual basis, with close monitoring of their efficacy and tolerability with concurrent antiretroviral therapy, taking into account potential drug-drug interactions. The decision to treat a patient or to wait for better treatment options, or to discontinue treatment should be made on an individual basis taking into account pre-treatment variables and the on-treatment HCV RNA kinetics.

Original languageEnglish
Pages (from-to)423-438
Number of pages16
JournalNew Microbiologica
Volume37
Issue number4
Publication statusPublished - Oct 1 2014

    Fingerprint

Keywords

  • Antiretroviral therapy
  • Boceprevir
  • HCV
  • HIV
  • PEG-IFN
  • RBV
  • Telaprevir

ASJC Scopus subject areas

  • Microbiology (medical)
  • Medicine(all)

Cite this

Armignacco, O., Andreoni, M., Sagnelli, E., Puoti, M., Bruno, R., Gaeta, G. B., Perno, C. F., Santantonio, T. A., Bonfanti, P., Bonora, S., Borderi, M., Castagna, A., D'Arminio Monforte, A., De Luca, A., Grossi, P., Guaraldi, G., Maggiolo, F., Mussini, C., Sagnelli, C., ... Taliani, G. (2014). Recommendations for the use of Hepatitis C virus protease inhibitors for the treatment of chronic Hepatitis C in HIV-infected persons. A position paper of the Italian Association for the Study of Infectious and Tropical Diseases. New Microbiologica, 37(4), 423-438.